Cheng Xu

8PUBLICATIONS
46CO-AUTHORS
Cancer therapy (excl. chemotherapy and radiation therapy)Predictive and prognostic markersApplied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (8)

|Jun 10, 2026
TQB2618 plus Penpulimab, Alone or in Combination with Chemotherapy, for Recurrent or Metastatic Nasopharyngeal Carcinoma: A Multicenter, Two-Cohort, Phase II Trial.

|May 21, 2026
Prognostic Value and Therapeutic Implications of MRI-Based Negative Lymph Nodes in Nasopharyngeal Carcinoma.

|Aug 26, 2025
MRI-based Middle Neck Involvement in Stage N1-N2 Nasopharyngeal Carcinoma: A Marker for Risk Stratification.

Guan-Jie Qin, Wei Jiang, Wu-Qi Zhang

|Feb 19, 2025
Reduced-volume radiotherapy versus conventional-volume radiotherapy after induction chemotherapy in nasopharyngeal carcinoma: An open-label, noninferiority, multicenter, randomized phase 3 trial.

Ling-Long Tang, Lin Chen, Gui-Qiong Xu

|Jun 17, 2022
Disparities in positive results and dissemination of randomized controlled trials in immuno-oncology.

Cheng Xu, Shu Zhang, Guang-Li Zhu

|Jun 16, 2022
Final Overall Survival Analysis of Gemcitabine and Cisplatin Induction Chemotherapy in Nasopharyngeal Carcinoma: A Multicenter, Randomized Phase III Trial.

Yuan Zhang, Lei Chen, Guo-Qing Hu

Pageof 2

Frequent Collaborators

6 joint publications

Jun Ma

4 joint publications

Ling-Long Tang

3 joint publications

Li-Zhi Liu

3 joint publications

Wen-Fei Li